Novartis gains ex-U.S. rights to Spark's gene thearpy

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE).

Spark will receive $105 million up front and is eligible for $65 million in milestones, plus royalties in the mid 20s. The milestones consist of $25 million if the drug is approved by EMA, and up to $40 million based on initial sales outside the U.S. ...